235 related articles for article (PubMed ID: 15841634)
1. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial.
Peris K; Campione E; Micantonio T; Marulli GC; Fargnoli MC; Chimenti S
Dermatol Surg; 2005 Mar; 31(3):318-23. PubMed ID: 15841634
[TBL] [Abstract][Full Text] [Related]
2. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
Vidal D; Matías-Guiu X; Alomar A
Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature.
Drehs MM; Cook-Bolden F; Tanzi EL; Weinberg JM
Dermatol Surg; 2002 May; 28(5):427-9. PubMed ID: 12030878
[TBL] [Abstract][Full Text] [Related]
4. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
Sterry W; Ruzicka T; Herrera E; Takwale A; Bichel J; Andres K; Ding L; Thissen MR
Br J Dermatol; 2002 Dec; 147(6):1227-36. PubMed ID: 12452875
[TBL] [Abstract][Full Text] [Related]
5. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up.
Schiessl C; Wolber C; Tauber M; Offner F; Strohal R
J Drugs Dermatol; 2007 May; 6(5):507-13. PubMed ID: 17679185
[TBL] [Abstract][Full Text] [Related]
6. Superficial and nodular basal cell carcinomas treated with an immune response modifier: a report of seven patients.
Bianchi L; Costanzo A; Campione E; Nisticò S; Chimenti S
Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():24-6. PubMed ID: 14616808
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of photodynamic therapy with methyl aminolevulinate in the treatment of superficial and nodular basal cell carcinoma: an open-label trial.
Surrenti T; De Angelis L; Di Cesare A; Fargnoli MC; Peris K
Eur J Dermatol; 2007; 17(5):412-5. PubMed ID: 17673385
[TBL] [Abstract][Full Text] [Related]
8. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.
Huber A; Huber JD; Skinner RB; Kuwahara RT; Haque R; Amonette RA
Dermatol Surg; 2004 Mar; 30(3):429-30. PubMed ID: 15008876
[TBL] [Abstract][Full Text] [Related]
9. Basal cell carcinoma: treatment with imiquimod.
Bukhardt Pérez MP; Ruiz-Villaverde R; Naranjo Díaz MJ; Blasco Melguizo J; Naranjo Sintes R
Int J Dermatol; 2007 May; 46(5):539-42. PubMed ID: 17472691
[TBL] [Abstract][Full Text] [Related]
10. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient.
Kagy MK; Amonette R
Dermatol Surg; 2000 Jun; 26(6):577-8; discussion 578-9. PubMed ID: 10848940
[TBL] [Abstract][Full Text] [Related]
11. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle.
Berman B; Sullivan T; De Araujo T; Nadji M
Br J Dermatol; 2003 Nov; 149 Suppl 66():59-61. PubMed ID: 14616354
[TBL] [Abstract][Full Text] [Related]
12. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
[TBL] [Abstract][Full Text] [Related]
13. Photodynamic therapy and imiquimod immunotherapy for basal cell carcinomas.
Nikkels AF; Piérard-Franchimont C; Nikkels-Tassoudji N; Bourguignon R; Piérard GE
Acta Clin Belg; 2005; 60(5):227-34. PubMed ID: 16398319
[TBL] [Abstract][Full Text] [Related]
14. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
[TBL] [Abstract][Full Text] [Related]
15. Treatment of a large superficial basal cell carcinoma with 5% imiquimod: a case report and review of the literature.
Chen TM; Rosen T; Orengo I
Dermatol Surg; 2002 Apr; 28(4):344-6. PubMed ID: 11966794
[TBL] [Abstract][Full Text] [Related]
16. An open case series of patients with basal cell carcinoma treated with topical 5% imiquimod cream.
Cowen E; Mercurio MG; Gaspari AA
J Am Acad Dermatol; 2002 Oct; 47(4 Suppl):S240-8. PubMed ID: 12271286
[TBL] [Abstract][Full Text] [Related]
17. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks.
Quirk C; Gebauer K; Owens M; Stampone P
Australas J Dermatol; 2006 Nov; 47(4):258-65. PubMed ID: 17034468
[TBL] [Abstract][Full Text] [Related]
18. The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin's syndrome.
Micali G; Lacarrubba F; Nasca MR; De Pasquale R
Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():19-23. PubMed ID: 14616807
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of imiquimod 5% cream for basal cell carcinoma in transplant patients.
Vidal D; Alomar A
Clin Exp Dermatol; 2004 May; 29(3):237-9. PubMed ID: 15115500
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma.
Bostanci S; Kocyigit P; Vural S; Heper AO; Botsali A
Dermatol Surg; 2018 Jan; 44(1):36-41. PubMed ID: 29016542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
